HIV 1 Infection Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
D
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
Not yet recruiting
  • Hypertension
  • +3 more
    • (no location specified)
    2022-04-05
    Apr 5, 2022
    U
    Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV
    Not yet recruiting
    • Resilience
    • +2 more
    • RISE+
    • Stress Reduction Control
    • (no location specified)
    2022-03-29
    Mar 29, 2022
    J
    Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)
    Withdrawn
    • Pregnancy
    • HIV-1-infection
    • Standard dose Truvada®
    • Pregnancy-adjusted dose Truvada®
    • (no location specified)
    2022-03-28
    Mar 28, 2022
    S
    Therapeutic Vaccination in Treated HIV Disease - 2021
    Completed
    • HIV-1-infection
    • PENNVAX-GP
    • +3 more
    • Los Angeles, California
    • +1 more
    2022-04-04
    Apr 4, 2022
    P
    Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection
    Recruiting
    • HIV-1-infection
    • Liuzhou, Guangxi, China
    • +2 more
    2022-03-31
    Mar 31, 2022
    U
    High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial - 2022
    Completed
    • HIV-1-infection
    • Hypovitaminosis D
    • 25-Hydroxyvitamin D
    • Lahore, Punjab/ lahore/Pakistan, Pakistan
    • +1 more
    2022-03-31
    Mar 31, 2022
    J
    Providing Unique Support for Health (PUSH) Study
    Active, not recruiting
    • HIV-1-infection
    • Mobile-enhanced Engagement Intervention
    • Baltimore, Maryland
      Center for Adolescent and Young Adult Health at Johns Hopkins Ha
    2022-03-29
    Mar 29, 2022
    U
    Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
    Active, not recruiting
    • HIV-1-infection
    • Salt Lake City, Utah
    • +7 more
    2022-03-30
    Mar 30, 2022
    U
    Uganda PrEP and Harm Reduction Evaluation
    Enrolling by invitation
    • HIV-1-infection
    • Integrating PrEP delivery
    • Kampala, Uganda
      Infectious Diseases Institute, Makerere University
    2022-03-28
    Mar 28, 2022
    W
    Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
    Recruiting
    • HPV Positive Oropharyngeal Squamous Cell Carcinoma
    • +2 more
    • 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
    • Saline Placebo
    • São Paulo, Brazil
    • +2 more
    2022-03-25
    Mar 25, 2022
    E
    Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART
    Recruiting
    • HIV-1-infection
    • EBT-101
    • San Francisco, California
    • +2 more
    2022-03-24
    Mar 24, 2022
    M
    Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg) - 2021
    Completed
    • HIV-1-infection
    • abacavir, dolutegravir and lamivudine dispersible tablets
    • Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
    • Montréal, Quebec, Canada
      Altasciences
    2022-03-10
    Mar 10, 2022
    U
    Effect of Methamphetamine on Residual Latent HIV Disease Study
    Recruiting
    • HIV-1-infection
    • Methamphetamine-dependence
    • Oral Methamphetamine
    • Placebo oral capsule
    • San Francisco, California
      San Francisco General Hospital
    2022-03-22
    Mar 22, 2022
    U
    Implementing Cabenuva in Arkansas HIV Programs
    Recruiting
    • HIV-1-infection
    • +2 more
    • Home visit delivery strategy
    • Little Rock, Arkansas
      University of Arkansas for Medical Sciences
    2022-03-07
    Mar 7, 2022
    G
    Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
    Not yet recruiting
    • HIV-1-infection
    • (no location specified)
    2022-03-07
    Mar 7, 2022
    T
    TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
    Not yet recruiting
    • HIV-1-infection
    • (no location specified)
    2022-03-15
    Mar 15, 2022
    D
    10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults
    Active, not recruiting
    • HIV-1-infection
    • 10E8.4/iMab
    • Orlando, Florida
    • +1 more
    2022-02-28
    Feb 28, 2022
    S
    Genotype-Informed Versus Empiric Management of VirEmia
    Recruiting
    • HIV-1-infection
    • Clinical management informed by HIV-1 genotypic resistance testing
    • Seboche, Butha-Buthe, Lesotho
    • +6 more
    2022-02-21
    Feb 21, 2022
    G
    Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
    Active, not recruiting
    • HIV-1-infection
    • B/F/TAF
    • Haifa, Israel
    • +4 more
    2022-03-08
    Mar 8, 2022
    C
    An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
    Active, not recruiting
    • HIV-1-infection
    • PRO 140 350
    • +2 more
    • San Francisco, California
      Quest Clinical Research
    2022-03-04
    Mar 4, 2022
    E
    Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
    Enrolling by invitation
    • HIV-1-infection
    • EBT-101
    • San Francisco, California
    • +2 more
    2022-03-04
    Mar 4, 2022
    S
    Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection
    Recruiting
    • HIV-1-infection
    • B/F/TAF
    • TDF-based triple ART regimen switching to B/F/TAF
    • Shanghai, Shanghai, China
    • +2 more
    2022-03-01
    Mar 1, 2022
    G
    Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
    Active, not recruiting
    • HIV-1-infection
    • Long Beach, California
    • +11 more
    2022-02-24
    Feb 24, 2022
    A
    Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD
    Recruiting
    • HIV-1-infection
      • Port-au-Prince, Bicentaire, Haiti
      • +13 more
      2022-02-22
      Feb 22, 2022
      A
      Pharmacokinetic Interactions of ENG Subdermal Implants With Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)
      Not yet recruiting
      • HIV-1-infection
      • Etonogestrel (ENG) Subdermal Implants
      • (no location specified)
      2022-02-22
      Feb 22, 2022